Deutsch
Englisch
| 2024 |
|---|
| Ukalovic, D., Leeb, B. F., Rintelen, B., Eichbauer-Sturm, G., Spellitz, P., Puchner, R., Herold, M., Stetter, M., Ferincz, V., Resch-Passini, J., Zwerina, J., Zimmermann-Rittereiser, M., & Fritsch-Stork, R. (2024). Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg. Arthritis Res Ther, 26(1), 44. doi: 10.1186/s13075-024-03277-x (IF: 4.9) |
| 2023 |
| Andrews, M. R., Kirchler, C., Mosor, E., Stamm, T., Duftner, C., & Fritsch-Stork, R. (2023). The impact of COVID-19 on rheumatology health-care workers and their scientific output: heavy lies the crown on women in rheumatology. The Lancet Rheumathology, -(-), e434-e436. doi: https://doi.org/10.1016/S2665-9913(23)00187-X (IF: 25.4) |
| Fritsch, G., Steltzer, H., Oberladstaetter, D., Zeller, C., & Prossinger, H. (2023). Artificial intelligence algorithms predict the efficacy of analgesic cocktails prescribed after orthopedic surgery. PLoS One, 18(2), e0280995. doi: 10.1371/journal.pone.0280995 (IF: 3.7) |
| Schreiber, K. I., Giles, N., Costedoat-Chalumeau, C., Dolhain, R. J. E. M., Et Al, ., Fonseca, J. E., Fritsch-Stork, R., Gerosa, M., & Et Al, . (2023). Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases. The Lancet Rheumathology, 5(9), e501-e506. doi: https://doi.org/10.1016/S2665-9913(23)00215-1 (IF: 25.4) |
| Werzowa, J., Behanova, M., Handisurya, A., Heger, F., Indra, A., Holzer, B., Dechat, T., Spitzer, S., Lederer, S., Kraus, D. A., Zwerina, J., & Fritsch-Stork, R. D. E. (2023). Response to Immunization against SARS-CoV-2 and Risk of Omicron Infection in Dialysis Patients: A Prospective Cohort Study. J Clin Med, 12(15), 4983. doi: 10.3390/jcm12154983 (IF: 4.4) |
| 2022 |
| Bonelli, M., Mrak, D., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., Haslacher, H., Mayer, M., Hofer, P., Redlich, K., Husar-Memmer, E., Fritsch-Stork, R., & Et Al, . (2022). Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Ann Rhaum Dis, 81(5), 687-694. doi: 10.1136/annrheumdis-2021-221558 |
| Kroese, S. J., Abheiden, C. N. H., Blomjous, B. S., Van Laar, J. M., Derksen, R. W. H. M., Bultink, I. E. M., Voskuyl, A. E., Lely, A. T., De Boer, M. A., De Vries, J. I. P., & Fritsch-Stork, R. D. E. (2022). Corrigendum to "Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study". J Immunol Res, -(-), -. doi: 10.1155/2022/9828675 |
| Kroese, S. J., De Hair, M. J. H., Limper, M., Lely, A. T., Van Laar, J. M., Derksen, R. H. W. M., & Fritsch-Stork, R. D. E. (2022). Corrigendum to "Hydroxychloroquine Use in Lupus Patients during Pregnancy Is Associated with Longer Pregnancy Duration in Preterm Births". J Immunol Res, -(-), -. doi: 10.1155/2022/9783521 |
| Ortmayr, G., Brunnthaler, L., Pereyra, D., Huber, H., Santol, J., Rumpf, B., Najarnia, S., Smoot, R., Ammon, D., Sorz, T., Fritsch, F., Schodl, M., Voill-Glaninger, A., Weitmayr, B., Födinger, M., Klimpfinger, M., Gruenberger, T., & Et Al, . (2022). Immunological Aspects of AXL/GAS-6 in the Context of Human Liver Regeneration. Hepatol Commun, 6(3), 576-592. doi: 10.1002/hep4.1832 |
| 2021 |
| Groot, N., Kardolus, A., Bijl, M., Dolhain, R. J. E. M., Teng, Y. K. O., Zirkzee, E., De Leeuw, K., Fritsch-Stork, R., Burdorf, A., Bultink, I. E., & Kamphuis, S. (2021). Effects of Childhood-onset Systemic Lupus Erythematosus on Academic Achievements and Employment in Adult Life. J Rheumatol, 48(6), 915-923. doi: 10.3899/jrheum.191004 |
| Kirchler, C., Husar-Memmer, E., Rappersberger, K., Thaler, K., & Fritsch-Stork, R. (2021). Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review. Type I Interferon as cardiovascular risk factor in systemic and cutaneous lupus erythematosus: A systematic review, 20(5), 102794. doi: 10.1016/j.autrev.2021.102794 |
| Wienke, J., Mertens, J. S., Garcia, S., Lim, J., Wijngaarde, C. A., Yeo, J. G., Meyer, A., Van Den Hoogen, L. L., Tekestra, J., Hoogendijk, J. E., Otten, H. G., Fritsch-Stork, R. D. E., De Jager, W., & Et Al, . (2021). Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk. Rheumatology, 60(2), 785-801. doi: 10.1093/rheumatology/keaa270 |
| 2020 |
| Stradner, M. H., Dejaco, C., Zwerina, J., & Fritsch-Stork, R. D. (2020). Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. Front Med, -(-), -. doi: 10.3389/fmed.2020.562142 |
| Van Den Hoogen, L., Van Der Heijden, E., Hillen, M., Mertens, J., Fritsch-Stork, R., Radstake, T., & Van Roon, J. (2020). Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: 'Biomarkers: to be or not to be' by Yavuz and Rönnblom. ann Rhaum Dis, 79(1), e9. doi: 10.1136/annrheumdis-2018-214651 |
| 2019 |
| Groot, N., Shaikhani, D., Teng, Y. K. O., De Leeuw, K., Bijl, M., Dolhain, R. J. E. M., Zirkzee, E., Fritsch-Stork, R., Bultink, I. E. M., & Kamphuis, S. (2019). Long-term clinical outcomes in a cohort of adults with childhood-onset Systemic Lupus Erythematosus. Arthritis Rheumatol, 71(2), 290-301. doi: 10.1002/art.40697 |
| Leavis, H., Zwerina, J., Manger, B., & Fritsch-Stork, R. (2019). Novel Developments in Primary Immunodeficiencies (PID)-a Rheumatological Perspective. Curr Rheumatol Rep, 21(10), 55. doi: 10.1007/s11926-019-0854-5 |
| Wienke, J., Bellutti Enders, F., Lim, J., Mertens, J., Van Den Hoogen, L., Wijngaarde, C., Yeo, J., Meyer, A., Otten, H., Fritsch-Stork, R., Kamphuis, S., Hoppenreijs, E., Armbrust, W., Van Den Berg, J., Hissink Muller, P., Tekstra, J., Hoogendijk, J., Deakin, C., De Jager, W., Van Roon, J., Van Der Pol, W., Nistala, K., Pilkington, C., De Visser, M., Arkachaisri, T., Radstake, T., Van Der Kooi, A., Nierkens, S., Wedderburn, L., Van Royen-Kerkhof, A., & Van Wijk, F. (2019). Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multi-cohort validation. Arthritis Rheumatol, 5(Epub), -. doi: 10.1002/art.40881 |
| 2018 |
| Cuppen, B. V. J., Rossato, M., Fritsch-Stork, R. D. E., Concepcion, A. N., Linn-Rasker, S. P., Bijlsma, J. W. J., Van Laar, J. M., Lafeber, F. P. J. G., & Radstake, R. T. (2018). RNA sequencing to predict response to TNF-α inhibitors reveals possible mechanism for nonresponse in smokers. Expert Rev Clin Immunil, 14(7), 623-633. doi: 10.1080/1744666X.2018.1480937 |
| Cuppen, B., Fritsch-Stork, R., Eekhout, I., De Jager, W., Marijnissen, A., Bijlsma, J., Custers, M., Van Laar, J., Lafeber, F., Welsing, P., & On Behalf Of All Society For Rheumatology Research Utrecht (sru) Investigators, .. (2018). Proteomics to predict the response to tumour necrosis factor-α inhibitors in rheumatoid arthritis using a supervised cluster-analysis based protein score. Scand J Rheumatol, 47(1), 12-21. doi: 10.1080/03009742.2017.1309061 |
| Hartman, E., Van Royen-Kerkhof, A., Jacobs, J., Welsing, P., & Fritsch-Stork, R. (2018). Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-an. Autoimmun Rev., 17(3), 316-322. doi: 10.1016/j.autrev.2018.01.007 |
| Van Den Hoogen, L. L., Palla, G., Bekker, C. P. J., Fritsch-Stork, R. D. E., Radstake, T. R. D. J., & Van Roon, J. A. G. (2018). Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores. RMD Open, 4(2), e000693. doi: 10.1136/rmdopen-2018-000693 |
| Van Den Hoogen, L. L., Van Der Heijden, E. H. M., Hillen, M. R., Mertens, J. S., Fritsch-Stork, R. D. E., Radstake, T. R. D. J., & Van Roon, J. A. G. (2018). Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Ann Rheum Dis, -(Epub), -. doi: 10.1136/annrheumdis-2018-214651 |
| Van Den Hoogen, L., Van Roon, J., Mertens, J., Wienke, J., Lopes, A., De Jager, W., Rossato, M., Pandit, A., Wichers, C., Van Wijk, F., Fritsch-Stork, R., & Radstake, T. (2018). Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis, 77(12), 1810-1814. doi: 10.1136/annrheumdis-2018-213497 |
| Van Der Linden, M., Van Den Hoogen, L., Westerlaken, G., Fritsch-Stork, R., Van Roon, J., Radstake, T., & Meyaard, L. (2018). Neutrophil extracellular trap release is associated with antinuclear antibodies in systemic lupus erythematosus and anti-phospholipid syndrome. Rheumatology, 57(7), 1228–1234. doi: 10.1093/rheumatology/key067 |
| 2017 |
| Cuppen, B., Pardali, K., Kraan, M., Marijnissen, A., Yrlid, L., Olsson, M., Bijilsma, J., Lafeber, F., & Fritsch-Stork, R. (2017). Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment. Rheumatol Int, 37(4), 531-536. doi: 10.1007/s00296-017-3653-1 |